ALPHA3

PIVOTAL PHASE 2 ALPHA3 TRIAL INITIATED

Allogene initiates the industry's first pivotal first line (1L) consolidation trial of an investigational allogeneic CAR T in LBCL

REDEFINING THE FUTURE OF CAR T

Doing what no autologous CAR T has done before

summit-logo-no-date

UNLOCKING THE FOURTH GREAT WAVE IN CANCER TREATMENT

Watch Allogene’s Dr. Zachary Roberts and STAT’s Laura Chang discuss how "off-the-shelf" CAR T products may again change the treatment of cancer.

summit_people

ALPHA3

PIVOTAL PHASE 2 ALPHA3 TRIAL INITIATED

Allogene initiates the industry's first pivotal first line (1L) consolidation trial of an investigational allogeneic CAR T in LBCL

REDEFINING THE FUTURE OF CAR T

Doing what no autologous CAR T has done before

summit-logo-no-date

UNLOCKING THE FOURTH GREAT WAVE IN CANCER TREATMENT

Watch Allogene’s Dr. Zachary Roberts and STAT’s Laura Chang discuss how "off-the-shelf" CAR T products may again change the treatment of cancer.

REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PRODUCT PLATFORM

Innovation

INNOVATION

  • Multiplex gene-engineering and gene-editing capabilities
  • Proprietary lymphodepletion platform
  • State-of-the-art manufacturing
  • Opportunity for product optimization
Pipeline Icon

KEY PROGRAMS

  • cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL
  • cema-cel: r/r CLL
  • ALLO-316: ccRCC
  • ALLO-329: autoimmune disease
Leadership

LEADERSHIP

  • A highly experienced management team that includes key pioneers of CAR T cell products
  • Singularly focused on the development of AlloCAR T™ products

WE DON’T JUST SEE THE FUTURE.

WE KNOW HOW TO GET THERE.

Our mission is to create and lead the next revolution in cell therapy by delivering to patients the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers, solid tumors and autoimmune disease.

WHY ALLOGENEIC CELL PRODUCTS HAVE THE POTENTIAL TO DO WHAT NO AUTOLOGOUS CAR T HAS DONE BEFORE

Assess

ACCESS

  • Potential to treat all
    eligible patients
  • Repeat dosing, if needed
  • No need for complex logistics
Cost

COST

  • Scalable and efficient manufacturing
  • Potential to treat 100+ patients from a single manufacturing run
  • Lower ancillary costs of care
Reliability

SPEED/RELIABILITY

  • "Off-the-shelf" for on-demand treatment
  • Less product variability, made from healthy T cells
Innovation

INNOVATION

  • Multiplex
    gene-engineering and gene-editing capabilities
  • Opportunity for product optimization

OUR PARTNERS

Antion-greyscale-light
Arbor_Bio_grayscale
Cellectis
foresight_logo
Notch Therapy
Servier

LATEST NEWS